ArticleJournal of the Korean Association of Oral and Maxillofacial Surgeons2020
miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers.
Article in Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Circulating microRNAs: a new era in early detection of oral squamous cell carcinoma (OSCC) - a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- The Role of Liquid Biopsy in the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis.Molecular diagnosis & therapy · 2023Pooled it
- The clinical implications of circulating microRNAs as potential biomarkers in screening oral squamous cell carcinoma.Frontiers in oncology · 2022Pooled it
- The oncogenic role of miR-155 on oral cancer progression and treatment strategies.Discover oncology · 2025Review
- MicroRNA-155 targets SOCS1 to inhibit osteoclast differentiation during orthodontic tooth movement.BMC oral health · 2023Article
- MicroRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β-catenin signaling pathway.BMC cancer · 2023Article
- Salivary level of microRNA-146a and microRNA-155 biomarkers in patients with oral lichen planus versus oral squamous cell carcinoma.BMC oral health · 2023Article
- Liquid biopsy in the assessment of microRNAs in oral squamous cell carcinoma: A systematic review.Journal of clinical and experimental dentistry · 2022Review
- The Functional Mechanism of MicroRNA in Oral Lichen Planus.Journal of inflammation research · 2022Review
- Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4.Frontiers in oncology · 2022Article
- The Role of microRNA in Pancreatic Cancer.Biomedicines · 2021Review
- MicroRNAs as Modulators of Oral Tumorigenesis-A Focused Review.International journal of molecular sciences · 2021Review
- Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives: Oral squamous cell carcinoma (OSCC) is one of the most common types of head and neck cancer. MicroRNAs, as new biomarkers, are recommended for diagnosis and treatment of different types of cancers. Bevacizumab, sold under the trade name Avastin, is a humanized whole monoclonal antibody that targets and blocks VEGF-A (vascular endothelial growth factor A; angiogenesis) and oncogenic signaling pathways. MATERIALS AND
methodsThis study comprised 50 cases suffering from OSCC and 50 healthy participants. Peripheral blood samples were collected in glass test tubes, and RNA extraction was started immediately. Expression levels of miR-155, miR-191, and miR-494 biomarkers in the peripheral blood of OSCC-affected individuals and healthy volunteers in vivo were evaluated using real-time PCR. The influence of Avastin on the expression levels of the aforementioned biomarkers in vitro and in the HN5 cell line was also investigated.
resultsExpression levels of miR-155, miR-191, and miR-494 in the peripheral blood of individuals affected by OSCC were higher than in those who were healthy. Moreover, Avastin at a concentration of 400 μM caused a decrease in the expression levels of the three biomarkers and a 1.5-fold, 3.5-fold, and 4-fold increase in apoptosis in the test samples compared to the controls in the HN5 cell line after 24, 48, and 72 hours, respectively.
conclusionThe findings of this study demonstrate that overexpression of miR-155, miR-191, and miR-494 is associated with OSCC, and Avastin is able to regulate and downregulate the expression of those biomarkers and increase apoptosis in cancerous cells in the HN5 cell line.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.